Zobrazeno 1 - 10
of 35
pro vyhledávání: '"Mehmet Asim Bilen"'
Autor:
Sean T Evans, Yash Jani, Caroline S Jansen, Ahmet Yildirim, Ecem Kalemoglu, Mehmet Asim Bilen
Publikováno v:
Cancer Biology & Therapy, Vol 25, Iss 1 (2024)
ABSTRACTThe introduction of novel immunotherapies has significantly transformed the treatment landscape of genitourinary (GU) cancers, even becoming the standard of care in some settings. One such type of immunotherapy, immune checkpoint inhibitors (
Externí odkaz:
https://doaj.org/article/082b3f99543f4a1ea7b9fa6358747071
Autor:
Dylan J. Martini, T. Anders Olsen, Subir Goyal, Yuan Liu, Sean T. Evans, Emilie Elise Hitron, Greta Anne Russler, Lauren Yantorni, Sarah Caulfield, Jacqueline T. Brown, Jamie M. Goldman, Bassel Nazha, Bradley C. Carthon, Wayne B. Harris, Omer Kucuk, Viraj A Master, Mehmet Asim Bilen
Publikováno v:
Journal of Immunotherapy and Precision Oncology, Pp 52-57 (2022)
Introduction: There are three combination immune checkpoint inhibitor (ICI)–based regimens in the first-line setting for metastatic renal cell carcinoma (mRCC). Currently, there is limited real-world data for clinical outcomes and toxicity in mRCC
Externí odkaz:
https://doaj.org/article/3b523ccfbd2e4ae9ba07ac843f39a4e8
Autor:
T. Anders Olsen, Tony Zibo Zhuang, Sarah Caulfield, Dylan J. Martini, Jacqueline T. Brown, Bradley C. Carthon, Omer Kucuk, Wayne Harris, Mehmet Asim Bilen, Bassel Nazha
Publikováno v:
Frontiers in Endocrinology, Vol 13 (2022)
Immune-oncologic (IO) therapy has revolutionized the treatment and management of oncologic disease. Immunotherapy functions by enhancing the host immune-systems ability to endogenously clear malignant cells, however, this activation can also lead to
Externí odkaz:
https://doaj.org/article/b0ec3f5e0a72497faac55787d11fe1bc
Autor:
Dylan J. Martini, T. Anders Olsen, Subir Goyal, Yuan Liu, Sean T. Evans, Benjamin Magod, Jacqueline T. Brown, Lauren Yantorni, Greta Anne Russler, Sarah Caulfield, Jamie M. Goldman, Bassel Nazha, Haydn T. Kissick, Wayne B. Harris, Omer Kucuk, Bradley C. Carthon, Viraj A. Master, Mehmet Asim Bilen
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
BackgroundImmune checkpoint inhibitors (ICI) have revolutionized the treatment of metastatic renal cell carcinoma (mRCC). Biomarkers for mRCC patients treated with ICI are limited, and body composition is underutilized in mRCC. We investigated the as
Externí odkaz:
https://doaj.org/article/9162907753ca46b98f276622972a2ce3
Autor:
Jonathan L. Wright, Alexander Sankin, Petros Grivas, Ignacio Duran, Ali Raza Khaki, Dimitrios Makrakis, Pedro C. Barata, Guru Sonpavde, Benjamin A. Gartrell, Vadim S. Koshkin, Evan Shreck, Lucia Carril-Ajuria, David J. Pinato, Mehmet Asim Bilen, Neeraj Agarwal, Mark P. Lythgoe, Giuseppe Di Lorenzo, Jayanshu Jain, Daniel Castellano, Ivan de Kouchkovsky, Rana R. McKay, Jure Murgic, Tyler F. Stewart, Michael Edward Devitt, Rafee Talukder, Pedro Isaacsson-Velho, Sandy T. Liu, Rafael Morales-Barrera, Lucia Alonso Buznego, Marcus Marie Moses, Leonidas Nikolaos Diamantopoulos, Aristotelis Bamias, Joseph J. Park, Ana Fröbe, Vivek Kumar, Alexandra Drakaki, Yousef Zakharia, Ariel Ann Nelson, Roubini Zakopoulou, Victor Sacristan Santos, Monika Joshi, Evan Y. Yu, Alejo Rodriguez-Vida, Michael Grant, Ajjai Alva, Christopher J. Hoimes, Abhishek Tripathi
Publikováno v:
BJU international, vol 130, iss 5
BJU Int
BJU Int
OBJECTIVES: To compare clinical outcomes with programmed-death ligand-1 immune checkpoint inhibitors (ICIs) in patients with advanced urothelial carcinoma (aUC) who have vs have not undergone radical surgery (RS) or radiation therapy (RT) prior to de
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e64617a8b9d10e6092cd0be747466efd
https://escholarship.org/uc/item/8678m8j9
https://escholarship.org/uc/item/8678m8j9
Autor:
Kenneth Ogan, Greta Russler, Jamie M. Goldman, Bassel Nazha, Benjamin Magod, Bradley C. Carthon, Deepak Ravindranathan, Shreyas S. Joshi, Haydn T. Kissick, Yuan Liu, T. Anders Olsen, Wayne Harris, Julie M. Shabto, Omer Kucuk, Jacqueline T. Brown, Subir Goyal, Sarah Caulfield, Lauren Yantorni, Mehmet Asim Bilen, Viraj A. Master, Sean Evans, Dylan J. Martini
Publikováno v:
Oncologist
Background Several immune checkpoint inhibitors (ICIs) are approved for the treatment of advanced urothelial carcinoma (UC). There are limited biomarkers for ICI-treated patients with UC. We investigated the association between body composition and c
Autor:
Yuan Liu, Julie M. Shabto, Bradley C. Carthon, Lauren Yantorni, Viraj A. Master, Dylan J. Martini, Omer Kucuk, Kenneth Ogan, Mehmet Asim Bilen, Shreyas S. Joshi, Jacqueline T. Brown, Deepak Ravindranathan, Wayne Harris, Sarah Caulfield, Haydn T. Kissick, Emilie Elise Hitron, Greta Russler
Publikováno v:
Oncologist
Background The modified Glasgow prognostic score (mGPS), a clinical tool that incorporates albumin and C-reactive protein, has proven useful in the prognostication of multiple cancers. Several immune checkpoint inhibitors (ICIs) have been approved fo
Autor:
Aristotelis Bamias, Vadim S. Koshkin, Victor Sacristan Santos, Matthew D. Galsky, Ana Fröbe, Joseph J. Park, David J. Pinato, Pedro Isaacsson Velho, Christopher J. Hoimes, Pavlos Msaouel, Jayanshu Jain, Daniel Castellano, Leonidas Nikolaos Diamantopoulos, Benjamin A. Gartrell, Neeraj Agarwal, Abhishek Tripathi, Ali Raza Khaki, Rafael Morales-Barrera, Ajjai Alva, Stepan M. Esagian, Lucia Carril-Ajuria, Jure Murgic, Tyler F. Stewart, Sandy T. Liu, Evan Shreck, Monika Joshi, Noah M. Hahn, Pedro C. Barata, Mehmet Asim Bilen, Lucia Alonso Buznego, Marcus Marie Moses, Ivan de Kouchkovsky, Vivek Kumar, Alexandra Drakaki, Yousef Zakharia, Ariel Ann Nelson, Roubini Zakopoulou, Petros Grivas, Evan Y. Yu, Alejo Rodriguez-Vida, Ignacio Duran, Alexander Sankin, Mark P. Lythgoe, Guru Sonpavde, Rana R. McKay, Michael Edward Devitt
Publikováno v:
BJU International. 128:196-205
Objectives: To compare clinical outcomes between patients with locally advanced (unresectable) or metastatic urothelial carcinoma (aUC) in the upper and lower urinary tract receiving immune checkpoint inhibitors (ICIs). Patients and methods: We perfo
Autor:
Toni K. Choueiri, Amin Nassar, Pier Vitale Nuzzo, Marina D. Kaymakcalan, David A. Braun, Mehmet Asim Bilen, Sarah Abou-Alaiwi, Dylan J. Martini, John A. Steinharter, Ziad Bakouny, Justin H. Fleischer, Aly-Khan A. Lalani, Xiao X. Wei, Wanling Xie, Bradley Alexander McGregor, Lauren C. Harshman
Publikováno v:
European Journal of Cancer. 135:203-210
Background Cabozantinib is approved for the first and subsequent line treatment of metastatic clear-cell renal cell carcinoma (ccRCC) based on trials in which most patients were immune checkpoint blockade (ICB) naive. With an expanding role of ICB in
Autor:
Yu Shyr, Kristen K. Ciombor, Gino Pineda, Yoanna Pumpalova, Chih-Yuan Hsu, Dana Backlund Cardin, Mehmet Asim Bilen, Laura W. Goff, Jordan Berlin, Ibrahim Halil Sahin, Shih Kai Chu, Christina Wu, Emily Pei Ying Lin, Satya Das, George A. Fisher, Sigurdis Haraldsdottir
Publikováno v:
Oncologist
Introduction Immune-related adverse event (IRAE) onset may represent a clinical biomarker for anti-programmed cell death protein 1 (PD-1) antibody response based on emerging evidence from patients with various advanced malignancies. This phenomenon h